Edition:
India

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

17.81USD
26 Apr 2018
Change (% chg)

$0.08 (+0.45%)
Prev Close
$17.73
Open
$17.68
Day's High
$17.83
Day's Low
$17.62
Volume
26,032
Avg. Vol
128,539
52-wk High
$30.06
52-wk Low
$16.24

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS.ACLARIS THERAPEUTICS - ‍POSITIVE RESULTS FROM 2 PHASE 2 CLINICAL TRIALS,WART-202,WART-203 OF A-101 45% TOPICAL SOLUTION,FOR TREATMENT OF COMMON WARTS​.ACLARIS - ‍A-101 45% MET ALL PRIMARY,SECONDARY ENDPOINTS OF EACH TRIAL, ACHIEVING CLINICALLY,STATISTICALLY SIGNIFICANT CLEARANCE OF COMMON WARTS​.  Full Article

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article

Aclaris Therapeutics says qtrly loss per share $0.63
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- ‍cash burn for 2017 is now estimated to be in range of $56 million to $59 million​.Aclaris Therapeutics Inc- ‍research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million​.  Full Article

Aclaris Therapeutics qtrly loss per share $0.50
Thursday, 3 Nov 2016 

Aclaris Therapeutics Inc : Qtrly loss per share $0.50 .Aclaris therapeutics reports third quarter 2016 financial results.  Full Article

Aclaris Therapeutics Qtrly loss per share $0.62
Thursday, 11 Aug 2016 

Aclaris Therapeutics Inc : Aclaris Therapeutics reports second quarter 2016 financial results .Qtrly loss per share $0.62.  Full Article

Aclaris Therapeutics to resale up to 1.1 mln shares by selling stockholders
Saturday, 18 Jun 2016 

Aclaris Therapeutics Inc : Files resale of up to 1.1 million shares of co's common stock by by the selling stockholders Source: (http://1.usa.gov/23gMebL ) Further company coverage: [ACRS.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Aclaris Therapeutics announces $20 mln private placement
Friday, 27 May 2016 

Aclaris Therapeutics Inc : Aclaris Therapeutics announces $20.0 million private placement . Entered into stock purchase agreement for private placement of 1.1 million shares of stock at a purchase price of $18.50 per share .Net proceeds from offering are expected to be used to fund research and development, including new JAK inhibitor programs.  Full Article

Aclaris Therapeutics Q1 loss per share $0.65
Wednesday, 11 May 2016 

Aclaris Therapeutics Inc : Qtrly net loss attributable to common stockholders was $13.0 million for q1 of 2016, compared to $3.3 million . Qtrly loss per share $0.65 . Q1 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S .Aclaris Therapeutics reports first quarter 2016 financial results.  Full Article

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage: